This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAPx Acquisition I（APXI.F）株式概要APx Acquisition Corp.Iは重要な事業を行っていない。 詳細APXI.F ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析マイナスの株主資本 収益が 100 万ドル未満 ( $0 )負債は営業キャッシュフローで十分にカバーされていない 過去5年間で収益は年間68.1%減少しました。 +2 さらなるリスクすべてのリスクチェックを見るAPXI.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$11.99該当なし内在価値ディスカウントEst. Revenue$PastFuture-2m6m2016201920222025202620282031Revenue US$1.0Earnings US$0.3AdvancedSet Fair ValueView all narrativesAPx Acquisition Corp. I 競合他社dMY Squared Technology GroupSymbol: OTCPK:DMYYMarket cap: US$56.2mWestin AcquisitionSymbol: NasdaqCM:WSTN.UMarket cap: US$80.6mTriLinc Global Impact FundSymbol: OTCPK:TRLCMarket cap: US$48.7mFlag Ship AcquisitionSymbol: NasdaqGM:FSHPMarket cap: US$55.4m価格と性能株価の高値、安値、推移の概要APx Acquisition I過去の株価現在の株価US$11.9952週高値US$12.0452週安値US$9.01ベータ0.0281ヶ月の変化0.76%3ヶ月変化1.18%1年変化20.02%3年間の変化16.69%5年間の変化n/aIPOからの変化n/a最新ニュースお知らせ • Mar 13Nasdaq to Delist the Ordinary Shares Class A, Unit, Warrant of APx Acquisition Corp INasdaq announced that it will delist the ordinary shares Class A, unit, warrant of APx Acquisition Corp. I. APx Acquisition Corp.’s stock was suspended on December 17, 2024 and has not traded on Nasdaq since that time.お知らせ • Dec 18Nasdaq Determines to Delist APx Acquisition Corp. I SecuritiesOn December 10, 2024, APX Acquisition Corp. I (the Company") received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (Nasdaq") stating that, pursuant to Nasdaq Listing Rule IM-5101-2 (Rule IM-5101-2"), the staff of Nasdaq (Staff") had determined that (i) the Company's securities will be delisted from Nasdaq, (ii) trading of the Company's Class A common stock, warrants, and units will be suspended at the opening of business on December 17, 2024 and (iii) a Form 25-NSE will be filed with the Securities and Exchange Commission (the SEC"), which will remove the Company's securities from listing and registration on Nasdaq. Under Rule IM-5101-2, a special purpose acquisition company must complete one or more business combinations within 36 months of the effectiveness of its initial public offering registration statement. Since the Company failed to complete its initial business combination by December 6, 2024, the Staff concluded that the Company did not comply with Rule IM-5101-2 and that the Company's securities are now subject to delisting. The Company intends to apply for the listing of its securities on the OTC market after they are delisted from Nasdaq. The delisting from Nasdaq and the commencement of trading on the OTC market does not affect the Company's previously announced business combination with OmnigenicsAI Corp, a Cayman Islands exempted company (Omnigenics"), as both parties continue to work to effectuate the closing of the business combination. Omnigenics will apply for listing of its securities on the Nasdaq Stock Market in connection with the closing of the business combination. The Company will remain a reporting entity under the Securities Exchange Act of 1934, as amended, with respect to continued disclosure of financial and operational information.お知らせ • Nov 03APX Acquisition Announces Nasdaq Delisting Notification for UnitsAs previously announced, on September 4, 2024, APX Acquisition Corp. I (the ‘Company’), received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market (‘Nasdaq’) indicating that since the Company's aggregate market value of its outstanding warrants was less than $1 million, the Company was no longer in compliance with the Nasdaq Global Market continued listing criteria set in Listing Rule 5452(b)(C) (the ‘Rule’), which requires the Company to maintain an aggregate market value of its outstanding warrants of at least $1 million (the ‘Notice’). The Company subsequently submitted a plan to regain compliance with the Rule (the ‘Compliance Plan’).On October 29, 2024, the Company received written notice from the Staff (the ‘November Notice’), stating that the Compliance Plan was not accepted as the Company had provided insufficient evidence to demonstrate that it can effect the Compliance Plan by its 36-month expiration date of December 6, 2024, at which time the Company's securities will be delisted from Nasdaq in accordance with IM-5101-2, irrespective of the Company's progress or lack thereof toward regaining compliance with the Rule, and that the Staff had determined to initiate procedures to delist the Company's warrants (and, as a result of the warrants' inclusion therein, the Company's units) from Nasdaq due to the Company's non-compliance. Pursuant to the Notice, unless the Company requests a hearing to appeal this determination by November 5, 2024, the Company's warrants and units will be suspended at the opening of business on November 5, 2024, and a Form 25-NSE will be filed with the SEC, which will remove the Company's warrants and units from listing and registration on Nasdaq (the ‘Warrant/Unit Delisting’). The Company does not intend to request a hearing. The Warrant/Unit Delisting does not affect the listing or trading of the Company's Class A ordinary shares on the Nasdaq Global Market, other than those contained within the units.お知らせ • Jun 06APx Acquisition Corp. I Receives Written Notice from Nasdaq Regarding Non-Compliance with the Nasdaq Listing Rule 5250(c)(1)On May 30, 2024, APx Acquisition Corp. I (the ‘Company’), received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market (‘Nasdaq’) indicating that since the Company had not yet filed its Form 10-K for the period ended December 31, 2023 nor had it filed its Form 10-Q for the period ended March 31, 2024, the Company was no longer in compliance with the Nasdaq Global Market continued listing criteria set forth in Listing Rule 5250(c)(1) (the ‘Rule’), which requires the Company to timely file all required periodic financial reports with the Securities and Exchange Commission through the EDGAR System (the ‘Notice’). The Notice additionally indicates that the Company, pursuant to the Listing Rules, has 60 calendar days, to submit a plan to regain compliance. If Nasdaq accepts the Company’s plan, the Company will have 180 calendar days from the referenced Form 10-K’s due date, or until September 27, 2024, to evidence compliance. If Nasdaq were to reject the Company’s plan, Nasdaq rules permit the Company to appeal the decision to a hearings panel. The Notice serves only as a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the Nasdaq Global Market. The Company intends to take action to submit a plan to regain compliance within the 60 calendar days submission period, and, if Nasdaq accepts the plan to regain compliance, to subsequently regain compliance with the Rule within the 180 calendar day compliance period. While the Company is exercising diligent efforts to maintain the listing of its securities on Nasdaq Global Market, there can be no assurance that the Company will be able to regain or maintain compliance with the Rule. In addition, if the Company does not meet the Rule’s requirement by the end of the 180 calendar day compliance period, Nasdaq could provide notice that the Company’s securities will become subject to delisting. In the event the Company receives notice that its securities are being delisted, Nasdaq rules permit the Company to appeal any delisting determination by the Nasdaq staff to a hearings panel.お知らせ • Mar 27OmnigenicsAI Corp entered into a definitive Business Combination Agreement to acquire APx Acquisition Corp. I (NasdaqGM:APXI).OmnigenicsAI Corp entered into a definitive Business Combination Agreement to acquire APx Acquisition Corp. I (NasdaqGM:APXI) on March 26, 2023. Pursuant to the BCA: (i) APx will merge with OmnigenicsAI, with APx being the surviving entity and becoming a wholly owned subsidiary of OmnigenicsAI and (ii) APx’s ordinary shares and warrants will be exchanged for ordinary shares and warrants of OmnigenicsAI. Upon closing, OmnigenicsAI shares and warrants are expected to be publicly listed on Nasdaq under the ticker symbols “OMNI” and “OMNIW”, respectively. The transaction is subject to the approval of APx’s shareholders. The transaction is expected to close mid-year, 2024. Greenberg Traurig, LLP, Maples & Calder (Cayman) LLP and Pérez Alati, Grondona, Benites & Arntsen acted as U.S./U.K., Cayman and Argentine legal counsel, respectively, to APx. EarlyBirdCapital, Inc. acted as M&A advisor to APx. Linklaters LLP, Ogier and Marval, O'Farrell & Mairal acted as U.S., Cayman and Argentine legal counsel, respectively, to OmnigenicsAI.Board Change • Mar 19Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Director Daniel Mudd was the last director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.最新情報をもっと見るRecent updatesお知らせ • Mar 13Nasdaq to Delist the Ordinary Shares Class A, Unit, Warrant of APx Acquisition Corp INasdaq announced that it will delist the ordinary shares Class A, unit, warrant of APx Acquisition Corp. I. APx Acquisition Corp.’s stock was suspended on December 17, 2024 and has not traded on Nasdaq since that time.お知らせ • Dec 18Nasdaq Determines to Delist APx Acquisition Corp. I SecuritiesOn December 10, 2024, APX Acquisition Corp. I (the Company") received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (Nasdaq") stating that, pursuant to Nasdaq Listing Rule IM-5101-2 (Rule IM-5101-2"), the staff of Nasdaq (Staff") had determined that (i) the Company's securities will be delisted from Nasdaq, (ii) trading of the Company's Class A common stock, warrants, and units will be suspended at the opening of business on December 17, 2024 and (iii) a Form 25-NSE will be filed with the Securities and Exchange Commission (the SEC"), which will remove the Company's securities from listing and registration on Nasdaq. Under Rule IM-5101-2, a special purpose acquisition company must complete one or more business combinations within 36 months of the effectiveness of its initial public offering registration statement. Since the Company failed to complete its initial business combination by December 6, 2024, the Staff concluded that the Company did not comply with Rule IM-5101-2 and that the Company's securities are now subject to delisting. The Company intends to apply for the listing of its securities on the OTC market after they are delisted from Nasdaq. The delisting from Nasdaq and the commencement of trading on the OTC market does not affect the Company's previously announced business combination with OmnigenicsAI Corp, a Cayman Islands exempted company (Omnigenics"), as both parties continue to work to effectuate the closing of the business combination. Omnigenics will apply for listing of its securities on the Nasdaq Stock Market in connection with the closing of the business combination. The Company will remain a reporting entity under the Securities Exchange Act of 1934, as amended, with respect to continued disclosure of financial and operational information.お知らせ • Nov 03APX Acquisition Announces Nasdaq Delisting Notification for UnitsAs previously announced, on September 4, 2024, APX Acquisition Corp. I (the ‘Company’), received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market (‘Nasdaq’) indicating that since the Company's aggregate market value of its outstanding warrants was less than $1 million, the Company was no longer in compliance with the Nasdaq Global Market continued listing criteria set in Listing Rule 5452(b)(C) (the ‘Rule’), which requires the Company to maintain an aggregate market value of its outstanding warrants of at least $1 million (the ‘Notice’). The Company subsequently submitted a plan to regain compliance with the Rule (the ‘Compliance Plan’).On October 29, 2024, the Company received written notice from the Staff (the ‘November Notice’), stating that the Compliance Plan was not accepted as the Company had provided insufficient evidence to demonstrate that it can effect the Compliance Plan by its 36-month expiration date of December 6, 2024, at which time the Company's securities will be delisted from Nasdaq in accordance with IM-5101-2, irrespective of the Company's progress or lack thereof toward regaining compliance with the Rule, and that the Staff had determined to initiate procedures to delist the Company's warrants (and, as a result of the warrants' inclusion therein, the Company's units) from Nasdaq due to the Company's non-compliance. Pursuant to the Notice, unless the Company requests a hearing to appeal this determination by November 5, 2024, the Company's warrants and units will be suspended at the opening of business on November 5, 2024, and a Form 25-NSE will be filed with the SEC, which will remove the Company's warrants and units from listing and registration on Nasdaq (the ‘Warrant/Unit Delisting’). The Company does not intend to request a hearing. The Warrant/Unit Delisting does not affect the listing or trading of the Company's Class A ordinary shares on the Nasdaq Global Market, other than those contained within the units.お知らせ • Jun 06APx Acquisition Corp. I Receives Written Notice from Nasdaq Regarding Non-Compliance with the Nasdaq Listing Rule 5250(c)(1)On May 30, 2024, APx Acquisition Corp. I (the ‘Company’), received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market (‘Nasdaq’) indicating that since the Company had not yet filed its Form 10-K for the period ended December 31, 2023 nor had it filed its Form 10-Q for the period ended March 31, 2024, the Company was no longer in compliance with the Nasdaq Global Market continued listing criteria set forth in Listing Rule 5250(c)(1) (the ‘Rule’), which requires the Company to timely file all required periodic financial reports with the Securities and Exchange Commission through the EDGAR System (the ‘Notice’). The Notice additionally indicates that the Company, pursuant to the Listing Rules, has 60 calendar days, to submit a plan to regain compliance. If Nasdaq accepts the Company’s plan, the Company will have 180 calendar days from the referenced Form 10-K’s due date, or until September 27, 2024, to evidence compliance. If Nasdaq were to reject the Company’s plan, Nasdaq rules permit the Company to appeal the decision to a hearings panel. The Notice serves only as a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the Nasdaq Global Market. The Company intends to take action to submit a plan to regain compliance within the 60 calendar days submission period, and, if Nasdaq accepts the plan to regain compliance, to subsequently regain compliance with the Rule within the 180 calendar day compliance period. While the Company is exercising diligent efforts to maintain the listing of its securities on Nasdaq Global Market, there can be no assurance that the Company will be able to regain or maintain compliance with the Rule. In addition, if the Company does not meet the Rule’s requirement by the end of the 180 calendar day compliance period, Nasdaq could provide notice that the Company’s securities will become subject to delisting. In the event the Company receives notice that its securities are being delisted, Nasdaq rules permit the Company to appeal any delisting determination by the Nasdaq staff to a hearings panel.お知らせ • Mar 27OmnigenicsAI Corp entered into a definitive Business Combination Agreement to acquire APx Acquisition Corp. I (NasdaqGM:APXI).OmnigenicsAI Corp entered into a definitive Business Combination Agreement to acquire APx Acquisition Corp. I (NasdaqGM:APXI) on March 26, 2023. Pursuant to the BCA: (i) APx will merge with OmnigenicsAI, with APx being the surviving entity and becoming a wholly owned subsidiary of OmnigenicsAI and (ii) APx’s ordinary shares and warrants will be exchanged for ordinary shares and warrants of OmnigenicsAI. Upon closing, OmnigenicsAI shares and warrants are expected to be publicly listed on Nasdaq under the ticker symbols “OMNI” and “OMNIW”, respectively. The transaction is subject to the approval of APx’s shareholders. The transaction is expected to close mid-year, 2024. Greenberg Traurig, LLP, Maples & Calder (Cayman) LLP and Pérez Alati, Grondona, Benites & Arntsen acted as U.S./U.K., Cayman and Argentine legal counsel, respectively, to APx. EarlyBirdCapital, Inc. acted as M&A advisor to APx. Linklaters LLP, Ogier and Marval, O'Farrell & Mairal acted as U.S., Cayman and Argentine legal counsel, respectively, to OmnigenicsAI.Board Change • Mar 19Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Director Daniel Mudd was the last director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Feb 08+ 1 more updateAPx Acquisition Corp. I Appoints Kyle Bransfield as Chief Executive OfficerAPx Acquisition Corp. I announced On February 6, 2024, effective immediately, Daniel Braatz resigned as Chairman of the board of directors (the “Board”) and Chief Executive Officer of the company. Mr. Braatz will remain as a director on the Board. Mr. Braatz informed the Company that his resignation was not the result of any disagreement with the Company related to its operations, policies or practices. On the same date, the Board appointed Kyle Bransfield as a director, Chairman of the Board, and Chief Executive Officer of the Company. No family relationship exists between Mr. Bransfield and any of the Company’s directors or executive officers.Board Change • Dec 31Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Dec 29APX Acquisition Corp. I Receives Nasdaq Notice on Late Filing of Its Form 10-QAPX Acquisition Corp. I announced that it received a deficiency letter (the "Letter") on December 21, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"). The Letter notified the Company that since the Company had not yet filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the "Form 10-Q"), the Company does not comply with Nasdaq's Listing Rule 5250(c)(1) relating to the Company's obligation to file periodic financial reports for continued listing. The Letter further stated that the Company has until February 19, 2024 to submit a plan (the "Plan") to regain compliance with respect to the delinquent reports. The Letter also stated that any staff exemption to allow the Company to regain compliance, if granted, will be limited to a maximum of 180 calendar days from the due date of the Form 10-Q, or May 12, 2024. If Nasdaq does not accept the Plan, the Company will have the opportunity to appeal that decision to the Nasdaq Hearings Panel. The Company will continue to work with its auditors with the objective of filing the Form 10-Q as soon as practicable and will work diligently to submit the Plan promptly and take the necessary steps to regain compliance as soon as practicable.お知らせ • Sep 15APx Acquisition Corp. I Announces the Resignation of Daniel Braatz as Chairman of the BoardOn September 8, 2023, effective immediately, the following officers of APx Acquisition Corp. I submitted the resignation of Daniel Braatz as Chairman of the Board. Daniel Braatz will remain as a director on the Board.お知らせ • Aug 17APx Acquisition Corp. I announced delayed 10-Q filingOn 08/15/2023, APx Acquisition Corp. I announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17APx Acquisition Corp. I announced delayed 10-Q filingOn 05/16/2023, APx Acquisition Corp. I announced that they will be unable to file their next 10-Q by the deadline required by the SEC.Seeking Alpha • Aug 25APx Acquisition receives non-compliance letter from NasdaqBlank check company APx Acquisition Corp. I (NASDAQ:APXI) has received a letter of non-compliance from Nasdaq over a failure to timely file its quarterly report. The stock exchange said it has not received APXI's quarterly report on Form 10-Q for the period ended Jun. 30. The company has until Oct. 24 to submit a plan to regain compliance. If the plan is approved by the stock exchange, APXI may be granted an extension of up to 180 calendar days from due date of the Form 10-Q, or until Feb. 20, 2023, to regain compliance. Source: Press Release株主還元APXI.FUS Capital MarketsUS 市場7D0%0.7%-4.1%1Y20.0%7.6%20.6%株主還元を見る業界別リターン: APXI.F過去 1 年間で7.6 % の収益を上げたUS Capital Markets業界を上回りました。リターン対市場: APXI.F過去 1 年間で20.6 % の収益を上げたUS市場を上回りました。価格変動Is APXI.F's price volatile compared to industry and market?APXI.F volatilityAPXI.F Average Weekly Movementn/aCapital Markets Industry Average Movement3.6%Market Average Movement7.2%10% most volatile stocks in US Market16.6%10% least volatile stocks in US Market3.1%安定した株価: APXI.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のAPXI.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2021n/aKyle Bransfieldapxcap.mx/platforms/APx Acquisition Corp Iは重要な業務を行っていない。同社は、1つまたは複数の企業や団体との合併、株式交換、資産買収、株式購入、組織再編、または同様の企業結合を行うことに重点を置いている。同社は2021年に設立され、テネシー州ナッシュビルを拠点としている。もっと見るAPx Acquisition Corp. I 基礎のまとめAPx Acquisition I の収益と売上を時価総額と比較するとどうか。APXI.F 基礎統計学時価総額US$57.94m収益（TTM）-US$1.55m売上高(TTM)n/a0.0xP/Sレシオ-37.5xPER（株価収益率APXI.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計APXI.F 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$1.55m収益-US$1.55m直近の収益報告Mar 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.32グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-29.3%APXI.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/12/26 11:53終値2025/12/05 00:00収益2025/03/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋APx Acquisition Corp. I 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 13Nasdaq to Delist the Ordinary Shares Class A, Unit, Warrant of APx Acquisition Corp INasdaq announced that it will delist the ordinary shares Class A, unit, warrant of APx Acquisition Corp. I. APx Acquisition Corp.’s stock was suspended on December 17, 2024 and has not traded on Nasdaq since that time.
お知らせ • Dec 18Nasdaq Determines to Delist APx Acquisition Corp. I SecuritiesOn December 10, 2024, APX Acquisition Corp. I (the Company") received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (Nasdaq") stating that, pursuant to Nasdaq Listing Rule IM-5101-2 (Rule IM-5101-2"), the staff of Nasdaq (Staff") had determined that (i) the Company's securities will be delisted from Nasdaq, (ii) trading of the Company's Class A common stock, warrants, and units will be suspended at the opening of business on December 17, 2024 and (iii) a Form 25-NSE will be filed with the Securities and Exchange Commission (the SEC"), which will remove the Company's securities from listing and registration on Nasdaq. Under Rule IM-5101-2, a special purpose acquisition company must complete one or more business combinations within 36 months of the effectiveness of its initial public offering registration statement. Since the Company failed to complete its initial business combination by December 6, 2024, the Staff concluded that the Company did not comply with Rule IM-5101-2 and that the Company's securities are now subject to delisting. The Company intends to apply for the listing of its securities on the OTC market after they are delisted from Nasdaq. The delisting from Nasdaq and the commencement of trading on the OTC market does not affect the Company's previously announced business combination with OmnigenicsAI Corp, a Cayman Islands exempted company (Omnigenics"), as both parties continue to work to effectuate the closing of the business combination. Omnigenics will apply for listing of its securities on the Nasdaq Stock Market in connection with the closing of the business combination. The Company will remain a reporting entity under the Securities Exchange Act of 1934, as amended, with respect to continued disclosure of financial and operational information.
お知らせ • Nov 03APX Acquisition Announces Nasdaq Delisting Notification for UnitsAs previously announced, on September 4, 2024, APX Acquisition Corp. I (the ‘Company’), received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market (‘Nasdaq’) indicating that since the Company's aggregate market value of its outstanding warrants was less than $1 million, the Company was no longer in compliance with the Nasdaq Global Market continued listing criteria set in Listing Rule 5452(b)(C) (the ‘Rule’), which requires the Company to maintain an aggregate market value of its outstanding warrants of at least $1 million (the ‘Notice’). The Company subsequently submitted a plan to regain compliance with the Rule (the ‘Compliance Plan’).On October 29, 2024, the Company received written notice from the Staff (the ‘November Notice’), stating that the Compliance Plan was not accepted as the Company had provided insufficient evidence to demonstrate that it can effect the Compliance Plan by its 36-month expiration date of December 6, 2024, at which time the Company's securities will be delisted from Nasdaq in accordance with IM-5101-2, irrespective of the Company's progress or lack thereof toward regaining compliance with the Rule, and that the Staff had determined to initiate procedures to delist the Company's warrants (and, as a result of the warrants' inclusion therein, the Company's units) from Nasdaq due to the Company's non-compliance. Pursuant to the Notice, unless the Company requests a hearing to appeal this determination by November 5, 2024, the Company's warrants and units will be suspended at the opening of business on November 5, 2024, and a Form 25-NSE will be filed with the SEC, which will remove the Company's warrants and units from listing and registration on Nasdaq (the ‘Warrant/Unit Delisting’). The Company does not intend to request a hearing. The Warrant/Unit Delisting does not affect the listing or trading of the Company's Class A ordinary shares on the Nasdaq Global Market, other than those contained within the units.
お知らせ • Jun 06APx Acquisition Corp. I Receives Written Notice from Nasdaq Regarding Non-Compliance with the Nasdaq Listing Rule 5250(c)(1)On May 30, 2024, APx Acquisition Corp. I (the ‘Company’), received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market (‘Nasdaq’) indicating that since the Company had not yet filed its Form 10-K for the period ended December 31, 2023 nor had it filed its Form 10-Q for the period ended March 31, 2024, the Company was no longer in compliance with the Nasdaq Global Market continued listing criteria set forth in Listing Rule 5250(c)(1) (the ‘Rule’), which requires the Company to timely file all required periodic financial reports with the Securities and Exchange Commission through the EDGAR System (the ‘Notice’). The Notice additionally indicates that the Company, pursuant to the Listing Rules, has 60 calendar days, to submit a plan to regain compliance. If Nasdaq accepts the Company’s plan, the Company will have 180 calendar days from the referenced Form 10-K’s due date, or until September 27, 2024, to evidence compliance. If Nasdaq were to reject the Company’s plan, Nasdaq rules permit the Company to appeal the decision to a hearings panel. The Notice serves only as a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the Nasdaq Global Market. The Company intends to take action to submit a plan to regain compliance within the 60 calendar days submission period, and, if Nasdaq accepts the plan to regain compliance, to subsequently regain compliance with the Rule within the 180 calendar day compliance period. While the Company is exercising diligent efforts to maintain the listing of its securities on Nasdaq Global Market, there can be no assurance that the Company will be able to regain or maintain compliance with the Rule. In addition, if the Company does not meet the Rule’s requirement by the end of the 180 calendar day compliance period, Nasdaq could provide notice that the Company’s securities will become subject to delisting. In the event the Company receives notice that its securities are being delisted, Nasdaq rules permit the Company to appeal any delisting determination by the Nasdaq staff to a hearings panel.
お知らせ • Mar 27OmnigenicsAI Corp entered into a definitive Business Combination Agreement to acquire APx Acquisition Corp. I (NasdaqGM:APXI).OmnigenicsAI Corp entered into a definitive Business Combination Agreement to acquire APx Acquisition Corp. I (NasdaqGM:APXI) on March 26, 2023. Pursuant to the BCA: (i) APx will merge with OmnigenicsAI, with APx being the surviving entity and becoming a wholly owned subsidiary of OmnigenicsAI and (ii) APx’s ordinary shares and warrants will be exchanged for ordinary shares and warrants of OmnigenicsAI. Upon closing, OmnigenicsAI shares and warrants are expected to be publicly listed on Nasdaq under the ticker symbols “OMNI” and “OMNIW”, respectively. The transaction is subject to the approval of APx’s shareholders. The transaction is expected to close mid-year, 2024. Greenberg Traurig, LLP, Maples & Calder (Cayman) LLP and Pérez Alati, Grondona, Benites & Arntsen acted as U.S./U.K., Cayman and Argentine legal counsel, respectively, to APx. EarlyBirdCapital, Inc. acted as M&A advisor to APx. Linklaters LLP, Ogier and Marval, O'Farrell & Mairal acted as U.S., Cayman and Argentine legal counsel, respectively, to OmnigenicsAI.
Board Change • Mar 19Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Director Daniel Mudd was the last director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Mar 13Nasdaq to Delist the Ordinary Shares Class A, Unit, Warrant of APx Acquisition Corp INasdaq announced that it will delist the ordinary shares Class A, unit, warrant of APx Acquisition Corp. I. APx Acquisition Corp.’s stock was suspended on December 17, 2024 and has not traded on Nasdaq since that time.
お知らせ • Dec 18Nasdaq Determines to Delist APx Acquisition Corp. I SecuritiesOn December 10, 2024, APX Acquisition Corp. I (the Company") received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (Nasdaq") stating that, pursuant to Nasdaq Listing Rule IM-5101-2 (Rule IM-5101-2"), the staff of Nasdaq (Staff") had determined that (i) the Company's securities will be delisted from Nasdaq, (ii) trading of the Company's Class A common stock, warrants, and units will be suspended at the opening of business on December 17, 2024 and (iii) a Form 25-NSE will be filed with the Securities and Exchange Commission (the SEC"), which will remove the Company's securities from listing and registration on Nasdaq. Under Rule IM-5101-2, a special purpose acquisition company must complete one or more business combinations within 36 months of the effectiveness of its initial public offering registration statement. Since the Company failed to complete its initial business combination by December 6, 2024, the Staff concluded that the Company did not comply with Rule IM-5101-2 and that the Company's securities are now subject to delisting. The Company intends to apply for the listing of its securities on the OTC market after they are delisted from Nasdaq. The delisting from Nasdaq and the commencement of trading on the OTC market does not affect the Company's previously announced business combination with OmnigenicsAI Corp, a Cayman Islands exempted company (Omnigenics"), as both parties continue to work to effectuate the closing of the business combination. Omnigenics will apply for listing of its securities on the Nasdaq Stock Market in connection with the closing of the business combination. The Company will remain a reporting entity under the Securities Exchange Act of 1934, as amended, with respect to continued disclosure of financial and operational information.
お知らせ • Nov 03APX Acquisition Announces Nasdaq Delisting Notification for UnitsAs previously announced, on September 4, 2024, APX Acquisition Corp. I (the ‘Company’), received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market (‘Nasdaq’) indicating that since the Company's aggregate market value of its outstanding warrants was less than $1 million, the Company was no longer in compliance with the Nasdaq Global Market continued listing criteria set in Listing Rule 5452(b)(C) (the ‘Rule’), which requires the Company to maintain an aggregate market value of its outstanding warrants of at least $1 million (the ‘Notice’). The Company subsequently submitted a plan to regain compliance with the Rule (the ‘Compliance Plan’).On October 29, 2024, the Company received written notice from the Staff (the ‘November Notice’), stating that the Compliance Plan was not accepted as the Company had provided insufficient evidence to demonstrate that it can effect the Compliance Plan by its 36-month expiration date of December 6, 2024, at which time the Company's securities will be delisted from Nasdaq in accordance with IM-5101-2, irrespective of the Company's progress or lack thereof toward regaining compliance with the Rule, and that the Staff had determined to initiate procedures to delist the Company's warrants (and, as a result of the warrants' inclusion therein, the Company's units) from Nasdaq due to the Company's non-compliance. Pursuant to the Notice, unless the Company requests a hearing to appeal this determination by November 5, 2024, the Company's warrants and units will be suspended at the opening of business on November 5, 2024, and a Form 25-NSE will be filed with the SEC, which will remove the Company's warrants and units from listing and registration on Nasdaq (the ‘Warrant/Unit Delisting’). The Company does not intend to request a hearing. The Warrant/Unit Delisting does not affect the listing or trading of the Company's Class A ordinary shares on the Nasdaq Global Market, other than those contained within the units.
お知らせ • Jun 06APx Acquisition Corp. I Receives Written Notice from Nasdaq Regarding Non-Compliance with the Nasdaq Listing Rule 5250(c)(1)On May 30, 2024, APx Acquisition Corp. I (the ‘Company’), received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market (‘Nasdaq’) indicating that since the Company had not yet filed its Form 10-K for the period ended December 31, 2023 nor had it filed its Form 10-Q for the period ended March 31, 2024, the Company was no longer in compliance with the Nasdaq Global Market continued listing criteria set forth in Listing Rule 5250(c)(1) (the ‘Rule’), which requires the Company to timely file all required periodic financial reports with the Securities and Exchange Commission through the EDGAR System (the ‘Notice’). The Notice additionally indicates that the Company, pursuant to the Listing Rules, has 60 calendar days, to submit a plan to regain compliance. If Nasdaq accepts the Company’s plan, the Company will have 180 calendar days from the referenced Form 10-K’s due date, or until September 27, 2024, to evidence compliance. If Nasdaq were to reject the Company’s plan, Nasdaq rules permit the Company to appeal the decision to a hearings panel. The Notice serves only as a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on the Nasdaq Global Market. The Company intends to take action to submit a plan to regain compliance within the 60 calendar days submission period, and, if Nasdaq accepts the plan to regain compliance, to subsequently regain compliance with the Rule within the 180 calendar day compliance period. While the Company is exercising diligent efforts to maintain the listing of its securities on Nasdaq Global Market, there can be no assurance that the Company will be able to regain or maintain compliance with the Rule. In addition, if the Company does not meet the Rule’s requirement by the end of the 180 calendar day compliance period, Nasdaq could provide notice that the Company’s securities will become subject to delisting. In the event the Company receives notice that its securities are being delisted, Nasdaq rules permit the Company to appeal any delisting determination by the Nasdaq staff to a hearings panel.
お知らせ • Mar 27OmnigenicsAI Corp entered into a definitive Business Combination Agreement to acquire APx Acquisition Corp. I (NasdaqGM:APXI).OmnigenicsAI Corp entered into a definitive Business Combination Agreement to acquire APx Acquisition Corp. I (NasdaqGM:APXI) on March 26, 2023. Pursuant to the BCA: (i) APx will merge with OmnigenicsAI, with APx being the surviving entity and becoming a wholly owned subsidiary of OmnigenicsAI and (ii) APx’s ordinary shares and warrants will be exchanged for ordinary shares and warrants of OmnigenicsAI. Upon closing, OmnigenicsAI shares and warrants are expected to be publicly listed on Nasdaq under the ticker symbols “OMNI” and “OMNIW”, respectively. The transaction is subject to the approval of APx’s shareholders. The transaction is expected to close mid-year, 2024. Greenberg Traurig, LLP, Maples & Calder (Cayman) LLP and Pérez Alati, Grondona, Benites & Arntsen acted as U.S./U.K., Cayman and Argentine legal counsel, respectively, to APx. EarlyBirdCapital, Inc. acted as M&A advisor to APx. Linklaters LLP, Ogier and Marval, O'Farrell & Mairal acted as U.S., Cayman and Argentine legal counsel, respectively, to OmnigenicsAI.
Board Change • Mar 19Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 4 non-independent directors. Director Daniel Mudd was the last director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 08+ 1 more updateAPx Acquisition Corp. I Appoints Kyle Bransfield as Chief Executive OfficerAPx Acquisition Corp. I announced On February 6, 2024, effective immediately, Daniel Braatz resigned as Chairman of the board of directors (the “Board”) and Chief Executive Officer of the company. Mr. Braatz will remain as a director on the Board. Mr. Braatz informed the Company that his resignation was not the result of any disagreement with the Company related to its operations, policies or practices. On the same date, the Board appointed Kyle Bransfield as a director, Chairman of the Board, and Chief Executive Officer of the Company. No family relationship exists between Mr. Bransfield and any of the Company’s directors or executive officers.
Board Change • Dec 31Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Dec 29APX Acquisition Corp. I Receives Nasdaq Notice on Late Filing of Its Form 10-QAPX Acquisition Corp. I announced that it received a deficiency letter (the "Letter") on December 21, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"). The Letter notified the Company that since the Company had not yet filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the "Form 10-Q"), the Company does not comply with Nasdaq's Listing Rule 5250(c)(1) relating to the Company's obligation to file periodic financial reports for continued listing. The Letter further stated that the Company has until February 19, 2024 to submit a plan (the "Plan") to regain compliance with respect to the delinquent reports. The Letter also stated that any staff exemption to allow the Company to regain compliance, if granted, will be limited to a maximum of 180 calendar days from the due date of the Form 10-Q, or May 12, 2024. If Nasdaq does not accept the Plan, the Company will have the opportunity to appeal that decision to the Nasdaq Hearings Panel. The Company will continue to work with its auditors with the objective of filing the Form 10-Q as soon as practicable and will work diligently to submit the Plan promptly and take the necessary steps to regain compliance as soon as practicable.
お知らせ • Sep 15APx Acquisition Corp. I Announces the Resignation of Daniel Braatz as Chairman of the BoardOn September 8, 2023, effective immediately, the following officers of APx Acquisition Corp. I submitted the resignation of Daniel Braatz as Chairman of the Board. Daniel Braatz will remain as a director on the Board.
お知らせ • Aug 17APx Acquisition Corp. I announced delayed 10-Q filingOn 08/15/2023, APx Acquisition Corp. I announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17APx Acquisition Corp. I announced delayed 10-Q filingOn 05/16/2023, APx Acquisition Corp. I announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Seeking Alpha • Aug 25APx Acquisition receives non-compliance letter from NasdaqBlank check company APx Acquisition Corp. I (NASDAQ:APXI) has received a letter of non-compliance from Nasdaq over a failure to timely file its quarterly report. The stock exchange said it has not received APXI's quarterly report on Form 10-Q for the period ended Jun. 30. The company has until Oct. 24 to submit a plan to regain compliance. If the plan is approved by the stock exchange, APXI may be granted an extension of up to 180 calendar days from due date of the Form 10-Q, or until Feb. 20, 2023, to regain compliance. Source: Press Release
